A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Recruiting · Phase 1, Phase 2 · NCT06427941
Conditions: Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $284,725
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 630
About the trial
- Sponsor
- BeOne Medicines
- Tested
- BGB-B2033 (drug), Tislelizumab (drug), Bevacizumab (drug)
- Dates
- Started 2024-07-23; completion 2028-10-31
- Results posted
- Not yet
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of BGB-B2033 alone or in combination with tislelizumab, with or without bevacizumab, in adults with advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-producing gastric cancer (GC), extragonadal yolk sac tumors, non-dysgerminomas, or glypican-3 (GPC3)-positive squamous non-small cell lung cancer (NSCLC). The study will also determine the recommended Phase 2 dose (RP2D) of BGB-B2033 when given alone or in combination with tislelizumab and bevacizumab. The main questions it aims to answer are: * Is BGB-B2033 safe and …
From ClinicalTrials.gov, last updated 2026-09-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $284,725 in research payments for this study in 2025 (5 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Vivek Subbiah, MD Medical Oncology · Stanford, CA
- Anwaar M. Saeed, M.D. Medical Oncology · Westwood, KS
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- UPMC Cancer Centers $150,949
- Florida Cancer Specialist (scri) - Fort Myers $133,776
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.